Introduction
Growth hormone receptors are known to exist on normal bone marrow haemopoetic stem cells. These are biologically active as seen in models in which exposure to recombinant human growth hormone (hGH) in vitro increases the colony-forming capacity of human myeloid and erythroid precursor cells and increases the colonyforming units in the spleen of inoculated mice. [1] [2] [3] [4] hGH produces better mobilization of marrow stem cells in mice and man, and hGH-treated mice recover more quickly after syngeneic transplantation of marrow cells. 4, 5 In a double-blind, placebo-controlled randomized trial, we explore the possibilities that hGH may be used in vivo to enhance bone marrow recovery after intensive treatment with cytotoxic chemotherapy and may also attenuate morbidity by reducing muscle loss, as seen in AIDS patients. [6] [7] [8] We also explore whether there is any direct or indirect anti-tumour effect on the malignant cells leading to prolongation of remission duration and survival because of the presence of receptors on these cells allowing increased apoptosis. Also, enhanced marrow recovery may permit optimization of chemotherapy scheduling. 9 
Methods

Study design
The study was designed as a prospective, randomized, double-blind, placebo-controlled trial. Patients were randomized (1:1) to receive hGH or placebo. Enrolment took place between July 2002 and September 2003 at the Royal Marsden Hospital. The trial design was such that patients would receive the study drug intravenously while they were admitted for a period of 2-4 weeks and were receiving other intravenous medication as part of their routine management. After the first 20 patients, it was apparent that the study drug was well tolerated and the patients were receptive to the idea of administering it subcutaneously on discharge. Hence, the trial duration was extended to 6 weeks after ethical approval. Patients started hGH/placebo when they commenced chemotherapy with or without total body irradiation as part of conditioning for their stem cell transplant (on day 1).
The study was approved by local research and ethics committee and individual patient consent was obtained (Local number 2128; NCT00300664).
Patients
Patients were eligible for randomization if they fulfilled the following criteria: a diagnosis of haematological malignancy, above 18 years of age and undergoing in-patient myelosuppressive chemotherapy and/or radiotherapy, no history of allergy to hGH, no history of hypertrophic cardiomyopathy or severe heart failure and serum creatinine below 150 mmol/l. The first 20 patients enrolled in the study received the study drug (hGH/placebo) only during their hospitalization (median of 24 days, range 9-42 days), but all subsequent patients were planned to receive it for 6 weeks (intravenously or subcutaneously depending upon the intravenous access). Patients were allowed to participate in the trial for the second or third time if they were still eligible and were being hospitalized for chemotherapy.
Procedures
The randomization code was computer generated by the statistical division of the Institute of Cancer Research and held by the pharmacy department independently. The nurses and physicians involved in the study were not aware of the randomization. Patients were randomized to receive either hGH or placebo in a 1:1 ratio. Pre-filled syringes (0.5 ml) labelled hGH/placebo were made in the chemotherapy division of the pharmacy for each patient and kept on the ward. Each patient had syringes prepared regularly for a week at a time.
All patients had routine full blood count and biochemistry tested daily until discharged from the hospital and then with every out-patient visit (usually twice a week to begin with and then weekly). Patients had the following investigations performed at the time of study entry and at the end of 6 weeks therapy: height, weight, triceps skin fold thickness (TFT) in mm, mid-arm circumference (MAC) in cm, serum IGF-1 levels, mannan binding lectin (MBL) levels and muscle strength in the quadriceps group of muscles. Dual-energy X-ray absorptiometry (DEXA) scans for total body composition on study entry and at 6 weeks was undertaken in the last 33 patients. Body mass index (BMI) was calculated as weight/(height) 2 (kg/m 2 ) and mid-arm muscle circumference (MAMC) was calculated as MAC (3.14 Â TFT in cm) cm 2 at baseline and at 6 weeks. Serious adverse events during the trial were reported to the trials office. Data on MBL levels and muscle strength will be presented elsewhere.
Statistical analysis and justification
The end points of the study were to assess BMI, MAC, TFT, MAMC at the start and end of therapy with hGH/ placebo, to assess tolerability of hGh/placebo, IGF-1 levels, albumin levels, recovery of neutrophils, platelets, days in hospital and overall and relapse-free survival. No estimates of the within-patient variation in these parameters in this group of patients were available on which to base sample size calculations. The literature suggests that as many as 90% patients will have significant weight loss and reduction in muscle mass during intensive therapy for haematological malignancies. [10] [11] [12] [13] If the percentage of patients losing weight and muscle mass is reduced by 20%, the study would have 80% power to detect the difference as Table 1 Trial profile of 119 patients receiving 150 courses (treatment protocols for these patients are shown in Table 2 The Mann-Whitney test for equality of medians was used to compare continuous variables and the w 2 test was used to compare frequencies. Time to haematological recovery, discharge from hospital and survival were estimated using the Kaplan-Meier method and comparisons between groups were made using log-rank method. The trial profile is shown in Table 1 . All 150 courses (Table 2) were used for the assessment of anthropometric data, hospital stay and haematological recovery. Data on 106 non-crossed-over patients (Table 2) were used for assessment of survival and relapse. Non-cross-over patients were defined as those who received either hGH or placebo alone (once, twice or thrice) throughout their treatment.
Drug doses and duration of treatment
Patients were randomized to receive 250 mg intravenously twice daily (500 mg/day), of hGH or placebo on the day of starting chemotherapy. When the platelet counts increased above 20 Â 10 9 /l, the study drug was administered at a dose of 500 mg subcutaneously once a day. The total duration of therapy was 6 weeks.
Results
Patients
A total of 150 courses of hGH/placebo were administered to 119 patients. Other than a significantly higher number of patients in complete remission (CR) in the placebo arm (P ¼ 0.005), baseline characteristics were well balanced between both the arms. Ninety-five patients were randomized once, 17 were randomized twice and seven on three occasions (Table 1) . Four patients withdrew from the study owing to personal reasons. The chemotherapy regimens received by the patients in the two arms were not significantly different and are shown in Table 2 . Various chemotherapy regimens (described in detail elsewhere) received by the patients were BF12 14 (11 hGH, 10 placebo), MACE 14, 15 (seven hGH, 10 placebo), DAT/DAM 15 (mylotarg with DA three hGH, eight placebo), UKALL XII/ German ALL induction/consolidation 16 (four hGH, two placebo) and others (four hGH, two placebo).
Non-cross-over patients
Of the 119 patients, 13 were crossed over between hGH or placebo, and hence 106 non-cross-over patients were exposed to either hGH (n ¼ 54; five twice and one thrice) or placebo (n ¼ 52; five twice) alone. These patient data were used for outcome analysis. Demography of the 106 patients is shown in Table 2 .
Anthropometric data There were no significant differences in the baseline anthropometric parameters between the hGH and placebo arm (Table 3) . At the end of 6 weeks of therapy, there was no difference in anthropometric measurements between the two groups. 
DEXA scans
Whole-body DEXA scans were performed at baseline in 33 patients and at 6 weeks in 28 patients (15 hGH and 13 placebo) to measure lean body mass, total fat and total bone mineral content. Lean body mass reduced by a mean of 5.4% in both groups. Total fat reduced by 7.3% in the hGH group and 8.2% in the placebo group and bone mineral content by 0.8% in the hGH group and 0.4% in the placebo group. No statistically significant differences were found between the two arms.
IGF-1 levels IGF-1 levels (mg/l) were comparable between the two arms at baseline. At the end of 6 weeks of therapy with hGH, there was a significant rise in the levels of IGF-1 with hGH compared with placebo (Po0.0005). The median IGF-I level at baseline in the hGH arm was 286 (range, 74-661) compared to 313.5 (range, 40-597) in the placebo arm (P ¼ 0.47). At the end of the study period, IGF-1 levels were available for 138 courses, median of 411 (range, 17-697) in the hGH arm compared to 280 (range, 4-642) in the placebo arm (Po0.0005).
Tolerability of the study drug hGH/placebo was well tolerated and no serious adverse events were attributable to the study drug. Patients received hGH for a median of 41 days (range, 2-42) and placebo for a median of 42 days (range, 10-42) (P ¼ 0.3). Five (7%) patients died during the study period at a median of 21 days (range, 10-40) in the hGH arm compared to four (5%) patients in the placebo arm (P ¼ 0.5).
Changes in glucose levels
Blood glucose levels (mmol/l) were available at the end of 6 weeks in 110 patients. For these, the median glucose at baseline was 6.1 (range, 4.5-18) in the hGH arm compared with 6.3 (range, 3.8-15) in the placebo arm (P ¼ 0.7). The level of glucose at the end of treatment was 5.9 (range, 3.5-15) in the hGH arm compared with 5.9 (3.9-15.4) in the placebo arm (P ¼ 0.4). The median change from baseline to the end of treatment was À2 in the hGH arm and À0.35 in the placebo arm (P ¼ 0.9). Eight patients received insulin in the hGH arm (two diabetic) compared with five patients (one diabetic) in the placebo arm (P ¼ 0.76).
Haematological recovery
Time to haematological recovery was estimated from the last day of chemotherapy. There was no difference in the time to neutrophil recovery above 0.5 Â There was no significant difference in time to discharge from hospital and the need for supportive care.
Overall survival
In the non-cross-over group of 106 patients, 54 are alive at a median of 805 days (range, 238-1006) and there was no difference in the overall survival (OS) between the two groups (hGH 32/54 alive, placebo 22/52 alive, P ¼ 0.12; Figure 3 ). There were 29 myeloma patients in the hGH arm and 21 in the placebo arm and there was no difference in their OS (HR ¼ 1.68, 95% CI 0.64-4.43, P ¼ 0.28).
Relapse Fifty-two of the 106 non-cross-over patients relapsed. Twelve patients were considered not evaluable for relapse as they were in relapse at the time of treatment and the response was not assessable (five in the hGH arm and seven in the placebo arm). Twenty-six of the 54 patients in the hGH arm and 26 of the 52 patients in the placebo arm relapsed (P ¼ 0.22; Figure 4 ). Of the 29 myeloma patients in the hGH arm and 21 in the placebo arm, there were no significant differences in relapse rate (HR ¼ 1.48, 95% CI 0.68-3.22; P ¼ 0.3) Recovery of platelets to 25 × 10 9 /l Figure 2 Log-rank comparison for recovery of platelets to 25 Â 10 9 /l between hGH (n ¼ 75) and placebo (n ¼ 75) arm.
Discussion
This is the first study in man to show faster haemopoietic recovery (platelets) in man by the use of hGH after intensive chemotherapy and supports the observation in mice that showed faster recovery after syngeneic transplant. 4 The only other study in man that indirectly supports this observation is that by Carlo-Stella et al. 5 which has shown that combining hGH with granulocyte-colony stimulating factor (G-CSF) leads to a significantly better collection of haemopoetic stem cells than with G-CSF alone. We did not see a significant effect on neutrophil recovery and days of hospitalization with hGH and this may be due to the small number of patients studied, or it is possible that hGH was acting as a co-factor for in vivo thrombopoietin.
We were mindful that hGH might be toxic when given to patients receiving intensive chemotherapy as it has been shown that there was increased mortality and morbidity with its use in supraphysiological doses in critically ill patients. 17 In the critically ill patients, those treated with hGH required insulin more frequently than in the placebo group. The dose of hGH used in our study was equivalent to 7 mg/kg, which is the upper end of the physiological dose required by an adult; this was much lower than that used in the study by Takala et al., 17 where patients received up to 5.3-8 mg/day of hGH. We knew before embarking on our study that blood glucose control would be important because, firstly hGH does not work well in the presence of a high blood glucose and secondly our patients often have high blood glucose levels due to the use of steroids as part of their anticancer treatment, anti-emetics or for treatment of graft-versus-host disease.
In our study, treatment-related mortality was similar in both the arms and we were reassured to find few side effects in this population of patients who are frequently very ill due to a combination of active disease, bone marrow failure and the side effects of treatment.
Despite the low dose of hGH in this pilot study, we clearly demonstrated a significant effect on platelet reconstitution and feel that further studies may warrant increasing the dose of hGh to maximize haemopoetic effect.
In the present study, hGH was given intraveneously to our thrombocytopenic patients because during this period subcutaneous injections cause unacceptable bruising, pain and morbidity and this does not affect bioavailability. Intravenous administration of hGH is probably not equivalent to subcutaneous administration, as the plasma half-life of growth hormone is only 15-20 min. It has previously been used intravenously in various studies without any concern relating to tolerability and toxicity. 18 In these intensively treated patients, there was a significant rise in IGF-1 levels at the end of hGH therapy, suggesting that resistance to growth hormone described previously in patients with severe systemic illness was not present. 19, 20 We also looked at the outcome of myeloma patients separately owing to the potential role of IGF-1 in supporting myeloma cell growth 21 and found no difference in relapse rate between the two arms.
In 1996, growth hormone was approved by the Food and Drug Administration (FDA) for the treatment of wasting and cachexia in patients with AIDS. This approval was based on evidence that growth hormone increases lean body mass and decreases fat mass in patients with AIDS, and a survival benefit was observed. [22] [23] [24] Cancer patients lose weight and muscle mass during chemotherapy. 10, 11 In this study, we hoped to see a possible protection in preventing muscle and protein loss during the immediate period after intensive chemotherapy. As this study period was too short to see muscle mass gain, the study was designed to assess prevention of muscle loss. We did not see any such benefit, possibly because the dose of hGH used may have been insufficient to elicit the responses shown in the patients with AIDS where higher pharmacologic doses were used (1.4-6 mg/day). 6, 7 The reason for not seeing an effect in our study was possibly because our patients had additional acute metabolic shutdown associated with intensive chemotherapy with or without sepsis. We also had the technical difficulty of accurate anthropometric assessment in this group of patients who have tremendous fluctuations in weight owing to changes in fluid balance.
There has been considerable concern for many years that hGH might either induce cancer or accelerate pre-existing, early or pre-cancerous states. [23] [24] [25] [26] In this study, we carefully looked for increased relapse rate, but could not find any. We therefore felt we were justified in embarking on this Probability of relapse in non-cross over patients Figure 4 Log-rank comparison for relapse-free survival in non-cross-over patients between hGH (n ¼ 54) and placebo (n ¼ 52) arm.
hGH and haemopoietic recovery after intensive chemotherapy B Sirohi et al present study, particularly to look for possible direct growth inhibition effect on tumour cells not previously looked for, within the background of an adjuvant effect with chemotherapy. Recent studies have shown an effect of hGH on cell survival by regulating nuclear factor-kappa B activity, leading to apoptosis in leukaemia cell lines. 9 Also, Cherbonnier et al. 9, 27 showed that hGH-transfected tumour cells engrafted in nude mice responded in vivo to chemotherapy with non-toxic doses of daunorubicin, whereas, under the same conditions, control tumour cells remained insensitive.
We show that it is safe to use hGH in this group of patients treated intensively with chemotherapy and/or stem cell transplantation, and that it does not increase relapse rate and improves platelet reconstitution. Future studies to confirm and assess its other effects are warranted.
